Post-translational modifications in bladder cancer: Expanding the tumor target repertoire

Bladder cancer (BCa) is the second most common urological malignancy after prostate cancer and a major cause of morbidity and death with enormous health-related cost. Approximately, 75% of newly diagnosed BCa patients have non-muscle invasive bladder cancer (NMIBC). Of this group, 70% of patients experience post-treatment recurrence that requires lifelong monitoring and up to 25% progress to more advanced disease [1,2]. In contrast to NMIBC, muscle-invasive bladder cancer (MIBC) is highly metastatic with a 5-year survival rate of approximately 50% in patients undergoing treatment [3].
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Seminars article Source Type: research